Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Joseph W. Dziedzic, President and CEO of Integer Holdings Corp (NYSE:ITGR), a $4.39 billion medical device manufacturer with robust financial health according to InvestingPro metrics, executed significant stock transactions on May 1, 2025. The company has demonstrated strong performance with 10.19% revenue growth over the last twelve months. Dziedzic sold common stock valued at approximately $41.75 million. The sales occurred at prices ranging from $122.45 to $126.18 per share.
In addition to the sales, Dziedzic acquired shares through stock option exercises, totaling about $3.12 million, at prices between $29.55 and $48.43 per share. Following these transactions, Dziedzic’s direct ownership stands at 47,000 shares.
The CEO also made a charitable gift of 24,000 shares, valued at $3 million, to a donor-advised fund. This gift was executed at a price of $125.085 per share. The company maintains a strong balance sheet with a healthy current ratio of 3.4, indicating solid liquidity management.
In other recent news, Integer Holdings reported first-quarter results that exceeded analyst expectations, leading to an increase in its stock price. The company posted adjusted earnings per share of $1.31, surpassing the analyst estimate of $1.23, and recorded revenue of $437.39 million, beating the consensus estimate of $428.51 million. This represented a 7% year-over-year increase, with organic growth contributing 6% to the revenue rise. Integer Holdings’ Cardio & Vascular segment was a significant growth driver, with sales increasing 17% year-over-year, supported by new product launches and recent acquisitions. The company raised its full-year adjusted EPS guidance to a range of $6.15 to $6.51, up from the previous analyst consensus of $6.07.
Additionally, Truist Securities analyst Richard Newitter raised the price target for Integer Holdings from $140 to $150 and reaffirmed a "Buy" rating on the shares. Newitter’s valuation reflects Integer’s consistent organic growth and contributions from mergers and acquisitions. The analyst highlighted Integer’s earnings per share growth, which is one and a half to two times that of its revenue growth. Integer’s first-quarter performance, which exceeded expectations, was a factor in the revised earnings forecast. The company’s financial health and growth trajectory continue to receive positive outlooks within the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.